药占比大变革 药企机会来了

2019-02-14 江边鸟 赛柏蓝

刚刚发布的《国务院办公厅关于加强三级公立医院绩效考核工作的意见》(国办发〔2019〕4号)提出了对公立医院4大部分14个方面55条的绩效考核指标,在明确“提供高质量的医疗服务是三级公立医院的核心任务”之后,对“一、医疗质量(三)合理用药”列出了六项用药考核指标代替原先的药占比考核。这样的改变应该说是科学合理的。原先粗放、单一的药占比考核,不仅不符合疾病治疗的客观规律,而且没有实际效果。有人总结

刚刚发布的《国务院办公厅关于加强三级公立医院绩效考核工作的意见》(国办发〔2019〕4号)提出了对公立医院4大部分14个方面55条的绩效考核指标,在明确“提供高质量的医疗服务是三级公立医院的核心任务”之后,对“一、医疗质量(三)合理用药”列出了六项用药考核指标代替原先的药占比考核。

这样的改变应该说是科学合理的。

原先粗放、单一的药占比考核,不仅不符合疾病治疗的客观规律,而且没有实际效果。

有人总结,控制药占比,不良后果多多:

一是侵犯了医生处方权,影响医生正常用药;二是干预了医院管理,凭空增添了不必要的管理工作量;三是违背了疾病治疗的自然需要,造成该用的药不用、不该用的药乱用;四是最关键之处在于医院医生实际上具有太多规避控制药占比的造假机会,最简单的一种就是多检查,增加检查费用开支。

所以,大多数医院在实施了药占比考核之后,虽然药占比有了一二十个百分比的大幅度下降,医保费用开支却不见减少甚至还有增加。

各地结合实际情况,已经用各种不同的方式,在架空药占比考核。

比如规定:国家基本药物不纳入公立医院药占比计算;国家谈判药品不纳入药占比计算;申报降价幅度大的抗癌药物不纳入药占比计算;省级谈判药品参照国家谈判药品执行不纳入药占比计算等措施。

这就把纳入不纳入药占比计算当做了一个推广使用基本药物和降低药价的工具。医药两界的反响都很大。

虽然控制医院药占比的初始政策目的十分明确:通过减少医院的不合理用药,遏制以药养医,降低医疗费用。但从实施效果看,这一政策作用受到制约。

这次国办〔2019〕4号文件在一、医疗质量(三)合理用药”列出的六项指标是:1、点评处方占处方总数的比例;2、抗菌药物使用强度;3、门诊患者基本药物处方占比;4、住院患者基本药物使用率;5、基本药物采购品种数占比;6、国家组织药品集中采购中标药品使用比例。

虽然这六项合理用药考核指标的实际实施效果如何尚不知道,抗菌药物使用强度以多大为宜也不好确定,但是,这些指标大力推进使用基本药物和国家集中采购中标药品的导向,却是十分明确的,而这两类药,应当说是相对低价、有效、副作用小,所以,方向正确。

特别是组织专家,对一张一张处方进行不知名的盲点,也即背靠背点评,肯定会对现在的过度用药进行有效的遏制。

现在医院有三大不当逐利:过度检查、过度用药、过度治疗。其中过度用药包括:品种过度:用了不必要的多种药,包括所谓辅助用药;数量过度:用了不必要的多量;时间过度:可以结束疗程了,还在继续用药;金额过度:在有疗效的范围内,选药宁选贵的,不选对的。有效的处方点评,有望大幅度改变这四种过度用药。

遏制不合理用药,对医疗过程中的药品消费,不能不说是一个利空。但这对医药行业的长期发展,却是一个重大利好。因为在过度用药即不合理用药状况下的药品消费增长,是以药品的畸形需求为前提的,是以回扣贿赂开道为前提的,是以医药费用的浪费为前提的,也是以牺牲病人的健康或者治疗机会为前提的。这不利于医药企业的社会形象树立和长远发展。

即使不考虑药品使用的社会责任,仅仅从医药企业自身的发展看,也是不可持续的。医院以医疗质量为目标,花大力气抓合理用药,正是给医药行业的发展指出了一个正确的方向。包括前述医院考核的一句话用于医药企业:“提供有疗效的药品是医药企业的核心任务”。

期望在医院绩效考核拨乱反正之后,医药企业能够改变自己的经营战略,放弃害人害己的带金销售,努力开发新的原研药品,努力增产市场适销的在产药品,配合医院的绩效考核,创造自己新的辉煌。

二十多年前,国家刚开始医改的时候,曾提过一个十分精辟的口号:看好病、不浪费。

看好病是医改的目标,不浪费是应当把握的代价,而浪费则应当是需要通过改革极力反对和避免的。哲人有云:“所得少于所可得,所费多于所当费,都是浪费。

”在医院改变三大不当逐利时,必然坚决唾弃三个过度。三个过度是寄生在医院医疗功能之上的三个癌症,它们过犹不及、物极必反,生生把医院救死扶伤的神圣职能,癌变成了病人深恶痛绝的恶性肿瘤!说其是当前医患关系对立、恶化、紧张的始作俑者,当不为过。

医院的主要功能是组织医生治病。医生的主要技能是治病。从合理用药的角度看医院医生,有两个截然相反的管理措施,其实质却是一样的:那就是表面上为了少用药的药占比控制,和直接为了多用药的处方回扣,两者的实质都是过分重视处方用药的经济销售作用,而漠视处方用药的疾病治疗作用。这是典型的本末倒置。

本来,用药应当是为疾病治疗之所需,经济销售则是实现疾病治疗的手段,如果倒因为果、倒本为末、倒手段为目的,必然带来经济方面的腐败和治病方面的失能。或许有人问:取消了药占比,医保如何控制药费?很简单,不要控制检查费,不要控制药费,不要控制治疗费,只需控制医疗总费用,即可!

国务院的公立医院绩效考核,使用了若干合理用药的相关指标代替粗放、单一使用药占比进行考核,是一个极大的进步。期待实际效果的出现。

笔者曾在讨论辅助用药管理时建议把“做好辅助用药临床应用管理有关工作”的要求,改成“做好药物临床应用管理有关工作”,也即做好所有药物的临床应用管理。

只有这样,才能完整、准确、有效地达到“提高临床合理用药水平的目的。”国办〔2019〕4号文件的“一、医疗质量(三)合理用药”正在往这个正确的方向调整。

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1509774, encodeId=011a1509e740b, content=<a href='/topic/show?id=1c8e8e333cb' target=_blank style='color:#2F92EE;'>#药占比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87333, encryptionId=1c8e8e333cb, topicName=药占比)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=762710134609, createdName=HNYYM, createdTime=Sat Feb 16 13:55:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360758, encodeId=780e360e58b1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Feb 16 07:45:38 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360745, encodeId=972f360e45ff, content=已学习并已分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231215/ac08b4d4cecf4bd3b9af86e00dcbca38/f6b6a60efd854ff191eb5c611ec7dd12.jpg, createdBy=8afb2071832, createdName=15938038573红旗飘飘, createdTime=Sat Feb 16 05:20:44 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360672, encodeId=b14e3606e22f, content=???????, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Fri Feb 15 08:33:36 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360670, encodeId=a88c3606e005, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Feb 15 08:23:39 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360669, encodeId=73c73606691f, content=什么情况, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Feb 15 08:07:01 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360667, encodeId=859a36066ea6, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Feb 15 07:36:43 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360666, encodeId=336a36066677, content=谢谢了学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Feb 15 07:36:31 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360659, encodeId=70f6360659c4, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Fri Feb 15 06:53:44 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360649, encodeId=6bb536064930, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Feb 15 00:15:25 CST 2019, time=2019-02-15, status=1, ipAttribution=)]
    2019-02-16 HNYYM
  2. [GetPortalCommentsPageByObjectIdResponse(id=1509774, encodeId=011a1509e740b, content=<a href='/topic/show?id=1c8e8e333cb' target=_blank style='color:#2F92EE;'>#药占比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87333, encryptionId=1c8e8e333cb, topicName=药占比)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=762710134609, createdName=HNYYM, createdTime=Sat Feb 16 13:55:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360758, encodeId=780e360e58b1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Feb 16 07:45:38 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360745, encodeId=972f360e45ff, content=已学习并已分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231215/ac08b4d4cecf4bd3b9af86e00dcbca38/f6b6a60efd854ff191eb5c611ec7dd12.jpg, createdBy=8afb2071832, createdName=15938038573红旗飘飘, createdTime=Sat Feb 16 05:20:44 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360672, encodeId=b14e3606e22f, content=???????, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Fri Feb 15 08:33:36 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360670, encodeId=a88c3606e005, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Feb 15 08:23:39 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360669, encodeId=73c73606691f, content=什么情况, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Feb 15 08:07:01 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360667, encodeId=859a36066ea6, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Feb 15 07:36:43 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360666, encodeId=336a36066677, content=谢谢了学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Feb 15 07:36:31 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360659, encodeId=70f6360659c4, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Fri Feb 15 06:53:44 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360649, encodeId=6bb536064930, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Feb 15 00:15:25 CST 2019, time=2019-02-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1509774, encodeId=011a1509e740b, content=<a href='/topic/show?id=1c8e8e333cb' target=_blank style='color:#2F92EE;'>#药占比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87333, encryptionId=1c8e8e333cb, topicName=药占比)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=762710134609, createdName=HNYYM, createdTime=Sat Feb 16 13:55:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360758, encodeId=780e360e58b1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Feb 16 07:45:38 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360745, encodeId=972f360e45ff, content=已学习并已分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231215/ac08b4d4cecf4bd3b9af86e00dcbca38/f6b6a60efd854ff191eb5c611ec7dd12.jpg, createdBy=8afb2071832, createdName=15938038573红旗飘飘, createdTime=Sat Feb 16 05:20:44 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360672, encodeId=b14e3606e22f, content=???????, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Fri Feb 15 08:33:36 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360670, encodeId=a88c3606e005, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Feb 15 08:23:39 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360669, encodeId=73c73606691f, content=什么情况, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Feb 15 08:07:01 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360667, encodeId=859a36066ea6, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Feb 15 07:36:43 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360666, encodeId=336a36066677, content=谢谢了学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Feb 15 07:36:31 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360659, encodeId=70f6360659c4, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Fri Feb 15 06:53:44 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360649, encodeId=6bb536064930, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Feb 15 00:15:25 CST 2019, time=2019-02-15, status=1, ipAttribution=)]
    2019-02-16 15938038573红旗飘飘

    已学习并已分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1509774, encodeId=011a1509e740b, content=<a href='/topic/show?id=1c8e8e333cb' target=_blank style='color:#2F92EE;'>#药占比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87333, encryptionId=1c8e8e333cb, topicName=药占比)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=762710134609, createdName=HNYYM, createdTime=Sat Feb 16 13:55:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360758, encodeId=780e360e58b1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Feb 16 07:45:38 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360745, encodeId=972f360e45ff, content=已学习并已分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231215/ac08b4d4cecf4bd3b9af86e00dcbca38/f6b6a60efd854ff191eb5c611ec7dd12.jpg, createdBy=8afb2071832, createdName=15938038573红旗飘飘, createdTime=Sat Feb 16 05:20:44 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360672, encodeId=b14e3606e22f, content=???????, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Fri Feb 15 08:33:36 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360670, encodeId=a88c3606e005, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Feb 15 08:23:39 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360669, encodeId=73c73606691f, content=什么情况, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Feb 15 08:07:01 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360667, encodeId=859a36066ea6, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Feb 15 07:36:43 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360666, encodeId=336a36066677, content=谢谢了学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Feb 15 07:36:31 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360659, encodeId=70f6360659c4, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Fri Feb 15 06:53:44 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360649, encodeId=6bb536064930, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Feb 15 00:15:25 CST 2019, time=2019-02-15, status=1, ipAttribution=)]
    2019-02-15 Janeinair

    ???????

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1509774, encodeId=011a1509e740b, content=<a href='/topic/show?id=1c8e8e333cb' target=_blank style='color:#2F92EE;'>#药占比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87333, encryptionId=1c8e8e333cb, topicName=药占比)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=762710134609, createdName=HNYYM, createdTime=Sat Feb 16 13:55:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360758, encodeId=780e360e58b1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Feb 16 07:45:38 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360745, encodeId=972f360e45ff, content=已学习并已分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231215/ac08b4d4cecf4bd3b9af86e00dcbca38/f6b6a60efd854ff191eb5c611ec7dd12.jpg, createdBy=8afb2071832, createdName=15938038573红旗飘飘, createdTime=Sat Feb 16 05:20:44 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360672, encodeId=b14e3606e22f, content=???????, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Fri Feb 15 08:33:36 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360670, encodeId=a88c3606e005, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Feb 15 08:23:39 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360669, encodeId=73c73606691f, content=什么情况, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Feb 15 08:07:01 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360667, encodeId=859a36066ea6, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Feb 15 07:36:43 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360666, encodeId=336a36066677, content=谢谢了学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Feb 15 07:36:31 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360659, encodeId=70f6360659c4, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Fri Feb 15 06:53:44 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360649, encodeId=6bb536064930, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Feb 15 00:15:25 CST 2019, time=2019-02-15, status=1, ipAttribution=)]
    2019-02-15 龙胆草

    学习谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1509774, encodeId=011a1509e740b, content=<a href='/topic/show?id=1c8e8e333cb' target=_blank style='color:#2F92EE;'>#药占比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87333, encryptionId=1c8e8e333cb, topicName=药占比)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=762710134609, createdName=HNYYM, createdTime=Sat Feb 16 13:55:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360758, encodeId=780e360e58b1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Feb 16 07:45:38 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360745, encodeId=972f360e45ff, content=已学习并已分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231215/ac08b4d4cecf4bd3b9af86e00dcbca38/f6b6a60efd854ff191eb5c611ec7dd12.jpg, createdBy=8afb2071832, createdName=15938038573红旗飘飘, createdTime=Sat Feb 16 05:20:44 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360672, encodeId=b14e3606e22f, content=???????, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Fri Feb 15 08:33:36 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360670, encodeId=a88c3606e005, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Feb 15 08:23:39 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360669, encodeId=73c73606691f, content=什么情况, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Feb 15 08:07:01 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360667, encodeId=859a36066ea6, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Feb 15 07:36:43 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360666, encodeId=336a36066677, content=谢谢了学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Feb 15 07:36:31 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360659, encodeId=70f6360659c4, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Fri Feb 15 06:53:44 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360649, encodeId=6bb536064930, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Feb 15 00:15:25 CST 2019, time=2019-02-15, status=1, ipAttribution=)]
    2019-02-15 smartxiuxiu

    什么情况

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1509774, encodeId=011a1509e740b, content=<a href='/topic/show?id=1c8e8e333cb' target=_blank style='color:#2F92EE;'>#药占比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87333, encryptionId=1c8e8e333cb, topicName=药占比)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=762710134609, createdName=HNYYM, createdTime=Sat Feb 16 13:55:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360758, encodeId=780e360e58b1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Feb 16 07:45:38 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360745, encodeId=972f360e45ff, content=已学习并已分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231215/ac08b4d4cecf4bd3b9af86e00dcbca38/f6b6a60efd854ff191eb5c611ec7dd12.jpg, createdBy=8afb2071832, createdName=15938038573红旗飘飘, createdTime=Sat Feb 16 05:20:44 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360672, encodeId=b14e3606e22f, content=???????, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Fri Feb 15 08:33:36 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360670, encodeId=a88c3606e005, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Feb 15 08:23:39 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360669, encodeId=73c73606691f, content=什么情况, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Feb 15 08:07:01 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360667, encodeId=859a36066ea6, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Feb 15 07:36:43 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360666, encodeId=336a36066677, content=谢谢了学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Feb 15 07:36:31 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360659, encodeId=70f6360659c4, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Fri Feb 15 06:53:44 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360649, encodeId=6bb536064930, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Feb 15 00:15:25 CST 2019, time=2019-02-15, status=1, ipAttribution=)]
    2019-02-15 txqjm

    谢谢了,学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1509774, encodeId=011a1509e740b, content=<a href='/topic/show?id=1c8e8e333cb' target=_blank style='color:#2F92EE;'>#药占比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87333, encryptionId=1c8e8e333cb, topicName=药占比)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=762710134609, createdName=HNYYM, createdTime=Sat Feb 16 13:55:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360758, encodeId=780e360e58b1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Feb 16 07:45:38 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360745, encodeId=972f360e45ff, content=已学习并已分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231215/ac08b4d4cecf4bd3b9af86e00dcbca38/f6b6a60efd854ff191eb5c611ec7dd12.jpg, createdBy=8afb2071832, createdName=15938038573红旗飘飘, createdTime=Sat Feb 16 05:20:44 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360672, encodeId=b14e3606e22f, content=???????, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Fri Feb 15 08:33:36 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360670, encodeId=a88c3606e005, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Feb 15 08:23:39 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360669, encodeId=73c73606691f, content=什么情况, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Feb 15 08:07:01 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360667, encodeId=859a36066ea6, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Feb 15 07:36:43 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360666, encodeId=336a36066677, content=谢谢了学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Feb 15 07:36:31 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360659, encodeId=70f6360659c4, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Fri Feb 15 06:53:44 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360649, encodeId=6bb536064930, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Feb 15 00:15:25 CST 2019, time=2019-02-15, status=1, ipAttribution=)]
    2019-02-15 txqjm

    谢谢了学习

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1509774, encodeId=011a1509e740b, content=<a href='/topic/show?id=1c8e8e333cb' target=_blank style='color:#2F92EE;'>#药占比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87333, encryptionId=1c8e8e333cb, topicName=药占比)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=762710134609, createdName=HNYYM, createdTime=Sat Feb 16 13:55:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360758, encodeId=780e360e58b1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Feb 16 07:45:38 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360745, encodeId=972f360e45ff, content=已学习并已分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231215/ac08b4d4cecf4bd3b9af86e00dcbca38/f6b6a60efd854ff191eb5c611ec7dd12.jpg, createdBy=8afb2071832, createdName=15938038573红旗飘飘, createdTime=Sat Feb 16 05:20:44 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360672, encodeId=b14e3606e22f, content=???????, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Fri Feb 15 08:33:36 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360670, encodeId=a88c3606e005, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Feb 15 08:23:39 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360669, encodeId=73c73606691f, content=什么情况, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Feb 15 08:07:01 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360667, encodeId=859a36066ea6, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Feb 15 07:36:43 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360666, encodeId=336a36066677, content=谢谢了学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Feb 15 07:36:31 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360659, encodeId=70f6360659c4, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Fri Feb 15 06:53:44 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360649, encodeId=6bb536064930, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Feb 15 00:15:25 CST 2019, time=2019-02-15, status=1, ipAttribution=)]
    2019-02-15 深海的鱼

    学习学习学习

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1509774, encodeId=011a1509e740b, content=<a href='/topic/show?id=1c8e8e333cb' target=_blank style='color:#2F92EE;'>#药占比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87333, encryptionId=1c8e8e333cb, topicName=药占比)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=762710134609, createdName=HNYYM, createdTime=Sat Feb 16 13:55:00 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360758, encodeId=780e360e58b1, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sat Feb 16 07:45:38 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360745, encodeId=972f360e45ff, content=已学习并已分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231215/ac08b4d4cecf4bd3b9af86e00dcbca38/f6b6a60efd854ff191eb5c611ec7dd12.jpg, createdBy=8afb2071832, createdName=15938038573红旗飘飘, createdTime=Sat Feb 16 05:20:44 CST 2019, time=2019-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360672, encodeId=b14e3606e22f, content=???????, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/f667a67c6692f1e356c51a346d5b382f.jpg, createdBy=7b7a2515105, createdName=Janeinair, createdTime=Fri Feb 15 08:33:36 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360670, encodeId=a88c3606e005, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Feb 15 08:23:39 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360669, encodeId=73c73606691f, content=什么情况, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Fri Feb 15 08:07:01 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360667, encodeId=859a36066ea6, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Feb 15 07:36:43 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360666, encodeId=336a36066677, content=谢谢了学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Fri Feb 15 07:36:31 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360659, encodeId=70f6360659c4, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Fri Feb 15 06:53:44 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=360649, encodeId=6bb536064930, content=学习了很有用不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Feb 15 00:15:25 CST 2019, time=2019-02-15, status=1, ipAttribution=)]
    2019-02-15 飛歌

    学习了很有用不错

    0

相关威廉亚洲官网

三部门:不得以费用总控、药占比等为理由 影响谈判药品供应

29日,国家医疗保障局办公室、人力资源社会保障部办公厅、国家卫生健康委办公厅联合发布《关于做好17种国家医保谈判抗癌药执行落实工作的通知》。通知指出,医保部门开展2018年医疗机构年底费用清算时,阿扎胞苷等17种抗癌药费用不纳入总额控制范围,对合理使用谈判药品的费用要按规定单独核算保障。

国家医保局:一品两规、药占比应适度调整

昨日,国家医保局副局长陈金甫表示,与4+7带量采购相背离、相冲突的一些政策,比如药占比、一品两规,应该做适当调整。

取消药占比,精细化控费仍在路上

《国务院办公厅关于加强三级公立医院绩效考核工作的意见》近日发布。许多人第一时间就注意到,该《意见》剔除了药占比、耗占比等医院考核指标。国家卫生健康委医政医管局局长张宗久表示,本次绩效考核用合理用药的相关指标,取代了单一药占比指标,更注重医务人员的处方合理性和患者用药的质量安全。这标志着公立医院绩效考核揭开了精细化控费的序幕。

30个药不占药占比

日前,安徽省医保局、省卫健委、省人社厅联合发布《关于做好“17+13+X”种抗癌药惠民落地工作的通知》。

国家医保局发通知,这些药不占药占比!

11月29日,国家医保局办公室、人社部办公厅、国家卫健委办公厅联合发布《关于做好17种国家医保谈判抗癌药执行落实工作的通知》(以下简称通知)。

控药占比药费不降反升,按病种付费才是降费之道?!

日前,卫健委成立后的首部《中国卫生健康统计年鉴2018》出版发行,和往年一样,其中有30个病种的医药费情况,通过分析发现,这两年严控药占比政策的实施,确实有些病种大幅度降低了“药占比”。